IGF1 and pituitary tumor: Overall, age >40 years, IGF-1 xULN at diagnosis and T2-hypointense pituitary tumor had an excellent discriminative ability to predict a >50% IGF-1 reduction after 6-month SRL treatment (AUC 0.98, 95%CI 0.93-1.0) (Supplementary Figure 1).